Early introduction of tolvaptan after cardiac surgery: a renal sparing strategy in the light of the renal resistive index measured by ultrasound

被引:0
作者
Tomoko S. Kato
Shunya Ono
Kan Kajimoto
Kenji Kuwaki
Taira Yamamoto
Atsushi Amano
机构
[1] Juntendo University School of Medicine,Department of Cardiovascular Surgery
来源
Journal of Cardiothoracic Surgery | / 10卷
关键词
Diuretics; Cardiac surgery; Renal function; Tolvaptan; Renal resistive index;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 186 条
[1]  
Marui A(2013)CREDO-Kyoto Investigators. Impact of occult renal impairment on early and late outcomes following coronary artery bypass grafting Interact Cardiovasc Thorac Surg 17 638-43
[2]  
Okabayashi H(2014)Incidence, dynamics, and prognostic value of acute kidney injury for death after cardiac surgery J Thorac Cardiovasc Surg 147 800-807
[3]  
Komiya T(2011)Acute kidney injury network classification predicts in-hospital and long-term mortality in patients undergoing elective coronary artery bypass grafting surgery Eur J Cardiothorac Surg 39 323-328
[4]  
Tanaka S(2009)Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil? Circ Heart Fail 2 56-62
[5]  
Furukawa Y(1990)Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD) Circulation 82 1724-9
[6]  
Kita T(2010)Loop diuretic therapy in heart failure: the need for solid evidence on a fluid issue Clin Cardiol 33 345-52
[7]  
Dardashti A(2011)Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study) Cardiovasc Drugs Ther 25 S33-45
[8]  
Ederoth P(2012)Short-term effects of low dose tolvaptan on hemodynamic parameters in patients with chronic heart failure J Cardiol. 60 462-9
[9]  
Algotsson L(2008)Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial J Am Coll Cardiol. 52 1540-5
[10]  
Brondén B(2014)Immediate administration of tolvaptan prevents the exacerbation of acute kidney injury and improves the mid-term prognosis of patients with severely decompensated acute heart failure Circ J. 78 911-21